WallStSmart

Hologic Inc (HOLX)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Hologic Inc generates 28% more annual revenue ($4.13B vs $3.22B). WST leads profitability with a 16.9% profit margin vs 13.2%. HOLX appears more attractively valued with a PEG of 1.66. WST earns a higher WallStSmart Score of 67/100 (B-).

HOLX

Buy

51

out of 100

Grade: C-

Growth: 2.7Profit: 6.5Value: 4.7Quality: 8.0
Piotroski: 5/9Altman Z: 2.37

WST

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HOLXUndervalued (+5.3%)

Margin of Safety

+5.3%

Fair Value

$79.30

Current Price

$76.01

$3.29 discount

UndervaluedFair: $79.30Overvalued
WSTSignificantly Overvalued (-32.8%)

Margin of Safety

-32.8%

Fair Value

$185.39

Current Price

$300.18

$114.79 premium

UndervaluedFair: $185.39Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HOLX1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.0%8/10

Strong operational efficiency at 23.0%

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

HOLX4 concerns · Avg: 3.5/10
PEG RatioValuation
1.664/10

Expensive relative to growth rate

P/E RatioValuation
31.5x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.5%4/10

2.5% revenue growth

EPS GrowthGrowth
-9.2%2/10

Earnings declined 9.2%

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
2.892/10

Expensive relative to growth rate

P/E RatioValuation
40.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : HOLX

The strongest argument for HOLX centers on Operating Margin.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : HOLX

The primary concerns for HOLX are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 40.1x leaves little room for execution misses.

Key Dynamics to Monitor

HOLX profiles as a value stock while WST is a growth play — different risk/reward profiles.

WST carries more volatility with a beta of 1.15 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

HOLX generates stronger free cash flow (215M), providing more financial flexibility.

Bottom Line

WST scores higher overall (67/100 vs 51/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hologic Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Hologic, Inc. is a medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?